The stock of Boston Scientific Corporation (BSX) has seen a -2.08% decrease in the past week, with a 2.33% gain in the past month, and a 10.85% flourish in the past quarter. The volatility ratio for the week is 1.88%, and the volatility levels for the past 30 days are at 2.04% for BSX. The simple moving average for the last 20 days is -0.98% for BSX stock, with a simple moving average of 14.64% for the last 200 days.
Is It Worth Investing in Boston Scientific Corporation (NYSE: BSX) Right Now?
Boston Scientific Corporation (NYSE: BSX) has a price-to-earnings ratio of 87.88x that is above its average ratio. Additionally, the 36-month beta value for BSX is 0.79. There are mixed opinions on the stock, with 22 analysts rating it as a “buy,” 4 rating it as “overweight,” 5 rating it as “hold,” and 0 rating it as “sell.”
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
The average price predicted by analysts for BSX is $58.44, which is $5.92 above the current price. The public float for BSX is 1.43B and currently, short sellers hold a 1.26% ratio of that float. The average trading volume of BSX on May 24, 2023 was 9.14M shares.
BSX) stock’s latest price update
The stock price of Boston Scientific Corporation (NYSE: BSX) has surged by 1.55 when compared to previous closing price of 51.50, but the company has seen a -2.08% decline in its stock price over the last five trading sessions. The Wall Street Journal reported on 08/08/22 that Boston Scientific Investigates Whistleblower Report in Vietnam
BSX Trading at 2.35% from the 50-Day Moving Average
After a stumble in the market that brought BSX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -3.45% of loss for the given period.
Volatility was left at 2.04%, however, over the last 30 days, the volatility rate increased by 1.88%, as shares surge +1.89% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +7.77% upper at present.
During the last 5 trading sessions, BSX fell by -2.52%, which changed the moving average for the period of 200-days by +27.08% in comparison to the 20-day moving average, which settled at $52.87. In addition, Boston Scientific Corporation saw 13.03% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BSX starting from Fitzgerald Joseph Michael, who sale 63,339 shares at the price of $53.60 back on May 16. After this action, Fitzgerald Joseph Michael now owns 213,859 shares of Boston Scientific Corporation, valued at $3,394,856 using the latest closing price.
Carruthers Wendy, the EVP, Human Resources of Boston Scientific Corporation, sale 11,671 shares at $53.49 during a trade that took place back on May 15, which means that Carruthers Wendy is holding 78,110 shares at $624,333 based on the most recent closing price.
Stock Fundamentals for BSX
Current profitability levels for the company are sitting at:
- +14.38 for the present operating margin
- +60.83 for the gross margin
The net margin for Boston Scientific Corporation stands at +5.50. The total capital return value is set at 6.88, while invested capital returns managed to touch 2.65. Equity return is now at value 4.80, with 2.60 for asset returns.
Based on Boston Scientific Corporation (BSX), the company’s capital structure generated 52.82 points at debt to equity in total, while total debt to capital is 34.56. Total debt to assets is 28.59, with long-term debt to equity ratio resting at 52.71. Finally, the long-term debt to capital ratio is 34.49.
When we switch over and look at the enterprise to sales, we see a ratio of 6.55, with the company’s debt to enterprise value settled at 0.12. The receivables turnover for the company is 6.77 and the total asset turnover is 0.39. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.51.
Conclusion
In conclusion, Boston Scientific Corporation (BSX) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
